Henlius Sees Revenues Soar In 2022, Q1 2023, As New Plant Bears Fruit
Chinese Biotech Offers Trastuzumab In EU, Five Biosimilars In The Clinic
Chinese player Shanghai Henlius Biotech has published unaudited financial results for the first three months of 2023, in the wake of its 2022 annual report.
You may also be interested in...
In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.
Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.